Sage plots comeback plan for its experimental oral antidepressant
Trials testing depression drugs invariably tend to disappoint. Perhaps the most keenly-anticipated depression trial of 2019, despite great analyst and investor optimism, also failed in patients with major depressive disorder (MDD), evaporating billions from its drugmaker Sage Therapeutics’ market value in early December.
The company — which last spring secured the landmark approval of its injectable postpartum depression drug Zulresso — now has an FDA-endorsed path forward for its experimental oral antidepressant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.